Ocumension TherapeuticsOCUTF 52 Gross Margin % is 50.02% as of Dec. 2025, which is 23% below its 10-year median of 64.74. GuruFocus rates OCUTF with a GF Score™ of 52/100 and a GF Value™ of $2.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 738 Biotechnology companies, Ocumension Therapeutics ranks worse than 64.63% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ocumension Therapeutics had a gross margin of 50.02% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ocumension Therapeutics Gross Margin % Related Terms
Ocumension Therapeutics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCUTF vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Ocumension Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumension Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ocumension Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ocumension Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ocumension Therapeutics (OCUTF) has a Gross Margin % of 50.02% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Ocumension Therapeutics and its competitors. This is 23% below median its historical median of 64.74. Over the past decade, Ocumension Therapeutics' Gross Margin % has ranged from 44.87 to 94.79. According to the industry distribution chart, Ocumension Therapeutics ranks #477 out of 738 companies in the Biotechnology industry, placing it in the top 64.6%.
Is Ocumension Therapeutics' Gross Margin % too high?
Ocumension Therapeutics' current Gross Margin % of 50.02% is 23% below median its 10-year median of 64.74. Over the past 10 years, this metric has ranged from a low of 44.87 to a high of 94.79. The Biotechnology industry median Gross Margin % is 60.94. Ocumension Therapeutics' value of 50.02% is 17.9% below this industry median. Based on the distribution chart, Ocumension Therapeutics ranks #477 out of 738 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ocumension Therapeutics has a GF Score™ of 52/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ocumension Therapeutics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ocumension Therapeutics ranks #477 out of 738 companies for Gross Margin %. This places Ocumension Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.94. Ocumension Therapeutics' value of 50.02% is 17.9% below this benchmark. Historically, Ocumension Therapeutics' own Gross Margin % has ranged from 44.87 to 94.79 over the past decade. While the company's 10-year median is 64.74 vs. the industry median of 60.94, Ocumension Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.94, based on 738 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ocumension Therapeutics's current Gross Margin % of 50.02% is 17.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ocumension Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumension Therapeutics's current Gross Margin % is 50.02%, which is 23% below median its own 10-year median of 64.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumension Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ocumension Therapeutics (OCUTF) is currently considered Possible Value Trap. The stock's GF Value™ is $2.82, compared to a current price of $0.70 — trading 75.2% below its estimated fair value. The current Gross Margin % is 50.02%, which is 23% below median its 10-year median of 64.74 and 17.9% below the Biotechnology industry median of 60.94. Ocumension Therapeutics' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ocumension Therapeutics (OCUTF), the current Gross Margin % is 50.02% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ocumension Therapeutics (OCUTF) Overvalued in 2026?
Based on GuruFocus' analysis, Ocumension Therapeutics stock appears to be undervalued.
The current stock price of $0.70 is trading 75.2% below its estimated GF Value™ of $2.82.
GuruFocus considers Ocumension Therapeutics to be Possible Value Trap.
Key valuation signals for OCUTF:
Gross Margin %: 50.02% (23% below median its 10-year median of 64.74)
GF Value™: $2.82 vs. price of $0.70 (75.2% below fair value)
Industry Position: 17.9% below the Biotechnology median (#477 of 738)
No single metric tells the full story. See the OCUTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
52GF Score
Get the complete analysis for OCUTF
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCUTF has been successfully added to your 
